Bodycote, a UK-listed company that heat-treats metals for industries like aerospace and automotive, has confirmed it is in the sights of two private equity firms. CVC Advisers and Veritas Capital have each tabled indicative cash proposals valuing the company at roughly £1.56 billion, according to a statement from the company. Under UK takeover rules, the bidders have until September 2 to make a firm offer or walk away.
What the bids look like
Reuters reports that CVC's proposal is up to 915 pence per share, comprising 907.8 pence in cash plus a 7.2 pence interim dividend. Veritas's offer is up to 914 pence, including the same dividend. Both represent a premium of about 22% to Bodycote's closing price of 750 pence on Tuesday.
Yet the market is already pricing in more. Bodycote shares finished Wednesday at 923 pence, above both indicative prices. That gap suggests investors believe a higher offer could emerge, either from one of the two bidders sweetening their terms or from a third party stepping in. When a stock trades above a known bid price, it often signals that the market expects a bidding war or an improved offer.
Why private equity is interested
Bodycote is a specialist in thermal processing—treating metal components to improve their strength, durability, and resistance to wear. It is a niche but essential service for manufacturers, and the company has a strong market position in Europe and North America. Private equity firms are often drawn to such businesses because they generate steady cash flows and operate in markets with high barriers to entry.
The interest from two buyers at nearly the same price also reflects a broader trend: private equity has been actively pursuing UK-listed companies, particularly those with solid fundamentals but modest growth prospects. The recent KKR deal to take medical-device maker Integer private and Pacific Equity Partners' offer for FleetPartners are just a couple of examples of this pattern.
What it means for investors
For everyday investors, the key takeaway is that Bodycote's board has not yet accepted either offer. The September 2 deadline is a hard stop: if the bidders do not make a firm offer by then, they must walk away under UK takeover rules, unless the deadline is extended with the consent of the takeover panel.
If you hold Bodycote shares, the current price above the bid levels suggests the market is betting on a higher outcome. But that is not guaranteed. If both bidders walk away, the share price could fall back to pre-bid levels. If one bidder returns with a higher offer, the stock could rise further.
It is also worth noting that the offers are in cash, which means shareholders would receive a fixed amount per share if a deal completes—no exposure to the buyer's future performance. Cash offers are often seen as more certain than share-based deals, but they also cap the upside if the company were to thrive on its own.
What to watch next
Investors will be watching for any updates from Bodycote's board, which has said it is evaluating the proposals. The board's recommendation will be crucial, as shareholders will vote on any final offer. Also watch for any regulatory hurdles, though a takeover of this size in the UK is unlikely to face major antitrust issues.
The broader context is also relevant. Private equity activity has remained robust even as private credit fundraising stays strong, and firms are increasingly looking at UK-listed companies as attractive targets. The expansion of private equity is a trend that could continue to shape markets.
For now, the ball is in the bidders' court. With the deadline looming, the next few weeks will determine whether Bodycote ends up in private hands—and at what price.
